ImageneBio (IMA) Competitors $8.60 -0.04 (-0.46%) As of 10/3/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMA vs. CGEN, LFVN, HURA, ZYBT, SKYE, BMEA, TIL, IKT, EXOZ, and KLRSShould you be buying ImageneBio stock or one of its competitors? The main competitors of ImageneBio include Compugen (CGEN), Lifevantage (LFVN), TuHURA Biosciences (HURA), Zhengye Biotechnology (ZYBT), Skye Bioscience (SKYE), Biomea Fusion (BMEA), Instil Bio (TIL), Inhibikase Therapeutics (IKT), eXoZymes (EXOZ), and Kalaris Therapeutics (KLRS). These companies are all part of the "pharmaceutical products" industry. ImageneBio vs. Its Competitors Compugen Lifevantage TuHURA Biosciences Zhengye Biotechnology Skye Bioscience Biomea Fusion Instil Bio Inhibikase Therapeutics eXoZymes Kalaris Therapeutics ImageneBio (NASDAQ:IMA) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation. Do institutionals & insiders have more ownership in IMA or CGEN? 75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 5.9% of ImageneBio shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, IMA or CGEN? ImageneBio has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Compugen has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500. Does the media prefer IMA or CGEN? In the previous week, ImageneBio had 3 more articles in the media than Compugen. MarketBeat recorded 4 mentions for ImageneBio and 1 mentions for Compugen. Compugen's average media sentiment score of 1.67 beat ImageneBio's score of -0.60 indicating that Compugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Compugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is IMA or CGEN more profitable? ImageneBio has a net margin of 0.00% compared to Compugen's net margin of -87.45%. ImageneBio's return on equity of -23.94% beat Compugen's return on equity.Company Net Margins Return on Equity Return on Assets ImageneBioN/A -23.94% -21.62% Compugen -87.45%-34.77%-16.82% Which has preferable earnings and valuation, IMA or CGEN? Compugen has higher revenue and earnings than ImageneBio. Compugen is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImageneBio$9.16M3.76-$49.23M-$7.68-1.12Compugen$27.86M5.22-$14.23M-$0.22-7.41 Do analysts recommend IMA or CGEN? ImageneBio currently has a consensus target price of $35.50, suggesting a potential upside of 312.79%. Compugen has a consensus target price of $4.00, suggesting a potential upside of 145.40%. Given ImageneBio's stronger consensus rating and higher possible upside, equities analysts clearly believe ImageneBio is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImageneBio 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Compugen 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryCompugen beats ImageneBio on 8 of the 15 factors compared between the two stocks. Get ImageneBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMA vs. The Competition Export to ExcelMetricImageneBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.61M$3.32B$6.07B$10.56BDividend YieldN/A2.27%5.68%4.70%P/E Ratio-1.1221.7377.3426.67Price / Sales3.76416.56575.61180.02Price / CashN/A46.6137.7361.25Price / Book0.279.9312.556.55Net Income-$49.23M-$52.59M$3.30B$277.26M7 Day Performance11.54%5.22%28,056.13%2.34%1 Month Performance1.78%13.01%28,993.65%9.26%1 Year Performance-57.84%25.19%35,460.84%30.76% ImageneBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMAImageneBio3.0036 of 5 stars$8.60-0.5%$35.50+312.8%-57.1%$34.61M$9.16M-1.1270News CoverageShort Interest ↑High Trading VolumeCGENCompugen1.7345 of 5 stars$1.44-0.3%$4.00+178.7%-8.4%$128.06M$27.86M-6.5270Positive NewsLFVNLifevantage4.2781 of 5 stars$9.78+0.2%$30.50+211.8%-16.9%$123.60M$228.53M13.16260Analyst DowngradeHURATuHURA Biosciences1.7273 of 5 stars$2.47-0.2%$12.67+413.7%N/A$123.42MN/A0.00N/ANews CoveragePositive NewsUpcoming EarningsZYBTZhengye BiotechnologyN/A$2.61+19.2%N/AN/A$123.10M$186.36M0.00278High Trading VolumeSKYESkye Bioscience2.4593 of 5 stars$3.93+1.3%$14.75+275.3%+32.7%$121.75MN/A-3.7111Analyst ForecastAnalyst RevisionBMEABiomea Fusion3.4226 of 5 stars$2.00-3.2%$9.50+376.2%-78.7%$118.72MN/A-0.6650News CoverageAnalyst ForecastTILInstil Bio2.7336 of 5 stars$17.56-5.0%$88.50+404.1%-65.4%$118.50MN/A-1.36410IKTInhibikase Therapeutics1.3527 of 5 stars$1.60+4.2%$6.50+307.5%+30.7%$118.11MN/A-0.596EXOZeXoZymes0.5189 of 5 stars$14.01-3.4%N/AN/A$117.54M$70K0.0029News CoveragePositive NewsKLRSKalaris Therapeutics1.105 of 5 stars$6.13-3.5%$3.00-51.1%N/A$114.63MN/A0.00110News CoverageAnalyst UpgradeShort Interest ↑ Related Companies and Tools Related Companies CGEN Competitors LFVN Competitors HURA Competitors ZYBT Competitors SKYE Competitors BMEA Competitors TIL Competitors IKT Competitors EXOZ Competitors KLRS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMA) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImageneBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImageneBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMA Stock Alerts